Incidence of self-reported tuberculosis treatment with community-wide universal testing and treatment for HIV and tuberculosis screening in Zambia and South Africa: A planned analysis of the HPTN 071 (PopART) cluster-randomised trial.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Corporate Authors:
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101231360 Publication Model: eCollection Cited Medium: Internet ISSN: 1549-1676 (Electronic) Linking ISSN: 15491277 NLM ISO Abbreviation: PLoS Med Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science, [2004]-
    • Subject Terms:
    • Abstract:
      Background: HIV is a potent risk factor for tuberculosis (TB). Therefore, community-wide universal testing and treatment for HIV (UTT) could contribute to TB control, but evidence for this is limited. Community-wide TB screening can decrease population-level TB prevalence. Combining UTT with TB screening could therefore significantly impact TB control in sub-Saharan Africa, but to our knowledge there is no evidence for this combined approach.
      Methods and Findings: HPTN 071 (PopART) was a community-randomised trial conducted between November 2013 to July 2018; 21 Zambian and South African communities (with a total population of approximately 1 million individuals) were randomised to arms A (community-wide UTT and TB screening), B (community-wide universal HIV testing with treatment following national guidelines and TB screening), or C (standard-of-care). In a cohort of randomly selected adults (18 to 44 years) enrolled between 2013 and 2015 from all 21 communities (total size 38,474; 27,139 [71%] female; 8,004 [21%] HIV positive) and followed-up annually for 36 months to measure the population-level impact of the interventions, data on self-reported TB treatment in the previous 12 months (self-reported TB) were collected by trained research assistants and recorded using a structured questionnaire at each study visit. In this prespecified analysis of the trial, self-reported TB incidence rates were measured by calendar year between 2014 and 2017/2018. A p-value ≤0.05 on hypothesis testing was defined as reaching statistical significance. Between January 2014 and July 2018, 38,287 individuals were followed-up: 494 self-reported TB during 104,877 person-years. Overall incidence rates were similar across all arms in 2014 and 2015 (0.33 to 0.46/100 person-years). In 2016 incidence rates were lower in arm A compared to C overall (adjusted rate ratio [aRR] 0.48 [95% confidence interval (95% CI) 0.28 to 0.81; p = 0.01]), with statistical significance reached. In 2017/2018, while incidence rates were lower in arm A compared to C, statistical significance was not reached (aRR 0.58 [95% CI 0.27 to 1.22; p = 0.13]). Among people living with HIV (PLHIV) incidence rates were lower in arm A compared to C in 2016 (RR 0.56 [95% CI 0.29 to 1.08; p = 0.08]) and 2017/2018 (RR 0.50 [95% CI 0.26 to 0.95; p = 0.04]); statistical significance was only reached in 2017/2018. Incidence rates in arms B and C were similar, overall and among PLHIV. Among HIV-negative individuals, there were too few events for cross-arm comparisons. Study limitations include the use of self-report which may have been subject to under-reporting, limited covariate adjustment due to the small number of events, and high losses to follow-up over time.
      Conclusions: In this study, community-wide UTT and TB screening resulted in substantially lower TB incidence among PLHIV at population-level, compared to standard-of-care, with statistical significance reached in the final study year. There was also some evidence this translated to a decrease in self-reported TB incidence overall in the population. Reduction in arm A but not B suggests UTT drove the observed effect. Our data support the role of UTT in TB control, in addition to HIV control, in high TB/HIV burden settings.
      Trial Registration: ClinicalTrials.gov: NCT01900977.
      Competing Interests: The authors have declared that no competing interests exist.
      (Copyright: © 2024 Telisinghe et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
    • References:
      PLoS Med. 2023 Sep 8;20(9):e1004278. (PMID: 37682971)
      Lancet Infect Dis. 2015 Sep;15(9):1066-1076. (PMID: 26112077)
      Epidemiol Infect. 2017 Sep;145(12):2500-2509. (PMID: 28748775)
      Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19485-9. (PMID: 20974976)
      Am J Trop Med Hyg. 2018 Dec;99(6):1407-1414. (PMID: 30277200)
      Sci Rep. 2019 Jul 24;9(1):10724. (PMID: 31341191)
      BMC Infect Dis. 2018 Sep 26;18(1):481. (PMID: 30257667)
      J Int AIDS Soc. 2015 Sep 25;18:20240. (PMID: 26411694)
      J Multidiscip Healthc. 2016 May 04;9:211-7. (PMID: 27217764)
      Am J Respir Crit Care Med. 2010 Oct 15;182(8):1080-5. (PMID: 20558626)
      Trop Med Infect Dis. 2023 Oct 03;8(10):. (PMID: 37888592)
      Public Health Action. 2016 Dec 21;6(4):247-251. (PMID: 28123962)
      Int J Tuberc Lung Dis. 2019 Feb 1;23(2):241-251. (PMID: 30808459)
      Int J Tuberc Lung Dis. 2011 Jul;15(7):933-7. (PMID: 21682967)
      BMJ Glob Health. 2019 May 22;4(3):e001371. (PMID: 31263580)
      N Engl J Med. 2019 Jul 18;381(3):207-218. (PMID: 31314965)
      J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):263-9. (PMID: 21317585)
      Public Health. 2021 Feb;191:48-54. (PMID: 33508661)
      BMJ Open. 2020 Apr 6;10(4):e034721. (PMID: 32265241)
      PLoS One. 2022 Aug 4;17(8):e0271917. (PMID: 35925972)
      J Int AIDS Soc. 2020 Feb;23(2):e25455. (PMID: 32091179)
      Curr Opin HIV AIDS. 2019 Nov;14(6):514-520. (PMID: 31567399)
      Trop Med Int Health. 2019 Sep;24(9):1114-1127. (PMID: 31310029)
      N Engl J Med. 2019 Jul 18;381(3):219-229. (PMID: 31314966)
      J Int AIDS Soc. 2019 Sep;22(9):e25394. (PMID: 31529618)
      Int J Tuberc Lung Dis. 2021 Dec 1;25(12):964-973. (PMID: 34886925)
      Trials. 2014 Feb 13;15:57. (PMID: 24524229)
      J Epidemiol Community Health. 2004 Aug;58(8):635-41. (PMID: 15252064)
      Trop Med Int Health. 2019 Mar;24(3):328-338. (PMID: 30589977)
      PLoS One. 2014 Jun 17;9(6):e99880. (PMID: 24937804)
    • Grant Information:
      UM1 AI068617 United States AI NIAID NIH HHS; UM1 AI069521 United States AI NIAID NIH HHS
    • Molecular Sequence:
      ClinicalTrials.gov NCT01900977
    • Publication Date:
      Date Created: 20240531 Date Completed: 20240531 Latest Revision: 20240904
    • Publication Date:
      20240904
    • Accession Number:
      PMC11142425
    • Accession Number:
      10.1371/journal.pmed.1004393
    • Accession Number:
      38820246